Heron Patrick J (CIK 1365617) reported 18 SEC Form 4 insider transactions across 4 companies over the past 18 months (most recent 2026-06-09). Recent activity: Buy ARQT (5,778 shares), Buy MIRM (159,277 shares), Buy MIRM (131,425 shares), Buy MBX (666,666 shares), Sell HLVX (8.5M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 5,778 | $0 |
| 2026-01-27 | Mirum Pharmaceuticals, Inc. (MIRM) | Director | Buy | 159,277 | $0 |
| 2026-01-27 | Mirum Pharmaceuticals, Inc. (MIRM) | Director | Buy | 131,425 | $9.0M |
| 2025-09-30 | MBX Biosciences, Inc. (MBX) | Director | Buy | 666,666 | $12.0M |
| 2025-09-17 | HilleVax, Inc. (HLVX) | Director | Sell | 8.5M | $16.6M |
| 2025-09-17 | HilleVax, Inc. (HLVX) | Director | Sell | 17,199 | $33,538 |
| 2025-06-25 | HilleVax, Inc. (HLVX) | Director | Buy | 17,199 | $0 |
| 2025-06-17 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 2,646 | $34,610 |
| 2025-06-16 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 7,609 | $0 |
| 2025-06-06 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 1,890 | $25,175 |
| 2025-06-06 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 378 | $5,069 |
| 2025-06-02 | Mirum Pharmaceuticals, Inc. (MIRM) | Director | Buy | 5,703 | $0 |
| 2025-05-23 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 2,520 | $34,423 |
| 2025-05-23 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 2,520 | $34,398 |
| 2025-05-19 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 2,520 | $34,322 |
| 2025-05-15 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 2,374 | $32,666 |
| 2025-05-15 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 6,300 | $86,688 |
| 2025-05-13 | Arcutis Biotherapeutics, Inc. (ARQT) | Director | Buy | 6,300 | $85,680 |
来源：SEC Form 4 申报文件 · 截至 2026-06-09